Last reviewed · How we verify

Antibody-Drug Conjugate

Sung-Soo Park · Phase 2 active Small molecule

Antibody-drug conjugates target specific cancer cells by binding to a protein on the cell surface, delivering a toxic payload to kill the cell.

Antibody-drug conjugates target specific cancer cells by binding to a protein on the cell surface, delivering a toxic payload to kill the cell. Used for Various types of cancer, including breast, lung, and ovarian cancer.

At a glance

Generic nameAntibody-Drug Conjugate
SponsorSung-Soo Park
Drug classAntibody-drug conjugate
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

This mechanism involves the use of monoclonal antibodies that are engineered to bind to a specific protein on the surface of cancer cells. Once bound, the antibody is internalized by the cell, releasing a toxic payload that kills the cell. This approach allows for targeted therapy with reduced harm to healthy cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: